Pulse Biosciences, Inc. (PLSE)
After hours:
| Previous Close | 8.05 |
| Open | 8.09 |
| Bid | 7.78 x 200 |
| Ask | 7.84 x 200 |
| Day's Range | 7.73 - 8.23 |
| 52 Week Range | 3.78 - 13.62 |
| Volume | |
| Avg. Volume | 164,962 |
| Market Cap | 431.862M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
HAYWARD, Calif., May 02, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has set the record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock"), as of
- Business Wire
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
HAYWARD, Calif., April 24, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.
- Business Wire
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
HAYWARD, Calif., March 28, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.
